Dr. Shimon Gross reports

DIAGNOSTEAR ACHIEVES MAJOR SCIENTIFIC MILESTONE WITH PUBLICATION OF TEARX CLINICAL STUDY IN CURRENT EYE RESEARCH JOURNAL

Diagnostear Technologies Inc.'s clinical manuscript entitled "Clinical Evaluation of TeaRx: A Point-of-Care Multi-Parameter Tear Film Test for Diagnosis, Stratification, and Prediction of Responsiveness to Cyclosporine A Therapy in Dry Eye Disease" has been published (as an open access manuscript) in the peer-reviewed journal Current Eye Research, a well-established international ophthalmology journal with an impact factor of approximately 2.1.

The study was conducted in collaboration with Prof. Sayan Basu and the Brien Holden Eye Research Centre at LV Prasad Eye Institute (LVPEI), Hyderabad, India, one of the world's leading ophthalmic research institutions.

The publication presents the clinical evaluation of Diagnostear's TeaRx Dry Eye platform, a non-invasive, multiparametric tear film test designed to bring objective, data-driven decision making to the diagnosis and management of dry eye disease (DED), a rapidly growing global market affecting hundreds of millions of patients worldwide.

The manuscript includes data from approximately 500 DED patients and 100 healthy controls, representing one of the largest cohorts evaluated to date for tear-based Dry Eye Diagnostics.

Key findings reported in the publication include:

1. TeaRx successfully differentiated severe dry eye disease patients from non-severe patients and healthy controls with strong diagnostic performance.
2. The platform demonstrated the ability to stratify patients according to disease severity, potentially enabling more personalized monitoring and treatment strategies.
3. TeaRx identified patients with severe Meibomian Gland Dysfunction (MGD), one of the leading causes of evaporative dry eye disease.
4. TeaRx demonstrated potential utility in predicting responsiveness to topical Cyclosporine A therapy, including a high negative predictive value, supporting improved patient selection and potentially reducing empirical treatment approaches.

The company is currently offering TeaRx dry eye test kits to clinical and academic collaborators and has already established research relationships with institutions and clinical research partners in multiple countries, including the United Kingdom, Australia, Israel and India. The company is also considering offering the test components for clinical laboratories to be validated and used as a laboratory developed test (LDT).

Dr. Shimon Gross, chief executive officer of Diagnostear Technologies, commented:

"We believe the publication of this manuscript in Current Eye Research represents an important validation milestone for TeaRx and Diagnostear's broader vision of transforming ophthalmology through tear-based precision diagnostics. Dry eye disease remains largely managed through subjective assessments and empirical treatment selection. TeaRx has the potential to provide clinicians with objective biological insights that may improve diagnosis, patient stratification and therapeutic decision making."

Prof. Sayan Basu added:

"These findings highlight the growing clinical relevance of tear biomarker analysis in ocular surface disease. TeaRx demonstrated encouraging performance in diagnosing and stratifying dry eye disease, while also showing potential utility in predicting therapeutic responsiveness, an increasingly important component of personalized ophthalmic care."

About Diagnostear Technologies Inc.

Diagnostear Technologies is a global leader in the development and commercialization of rapid, point-of-care, multiparametric diagnostic tests for ocular diseases. By leveraging the analysis of tear fluid composition, the company is developing innovative diagnostic solutions designed to support earlier detection, objective disease assessment, personalized treatment selection and improved patient outcomes in ophthalmology.

We seek Safe Harbor.